Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

New research suggests that a ctDNA assay can detect colorectal cancer recurrence months before it is detected via imaging.

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.

Tumor-infiltrating clonal hematopoiesis was associated with a greater risk of recurrence or death in patients with non-small-cell lung cancer.

In reducing federal funding and downsizing federal health agencies, the Trump administration is impeding cancer research.

Induction chemotherapy followed by IMRT is noninferior to CCRT for locoregionally advanced nasopharyngeal carcinoma, data suggest.

Researchers found that colibactin-induced mutational signatures were enriched in early-onset colorectal cancer cases.

Infection is a common cause of death in the first year after diagnosis with lower-risk myelodysplastic syndromes, data suggest.

Tepylute is now supplied as a multiple-dose vial containing 100 mg of thiotepa in addition to the previously approved single-dose vial containing 15 mg.

The FDA has issued a complete response letter to Telix Pharmaceuticals regarding TLX101-CDx for the imaging of gliomas.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.